TY - JOUR
T1 - Cohort profile
T2 - Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19 - Providing the evidence base for health care services (CONVALESCENCE) in the UK
AU - Jamieson, Alexandra
AU - Saikhan, Lamia Al
AU - Raman, Betty
AU - Alghamdi, Lamis
AU - Cheetham, Nathan J.
AU - Conde, Pauline
AU - Dobson, Richard
AU - Fernández-Sanlés, Alba
AU - Folarin, Amos
AU - Goudswaard, Lucy J.
AU - Hamill Howes, Lee
AU - Jones, Siana
AU - Neubauer, Stefan
AU - Orini, Michele
AU - Pierce, Iain
AU - Ranjan, Yatharth
AU - Rapala, Alicja
AU - Smith, Stephen M.
AU - Sudre, Carole
AU - Thompson, Ellen J.
AU - Wild, James
AU - Williams, Dylan
AU - Wong, Andrew
AU - Steves, Claire J.
AU - Timpson, Nic
AU - Chaturvedi, Nishi
AU - Hughes, Alun
N1 - Publisher Copyright:
© Published by the BMJ Publishing Group Limited.
PY - 2025/6/5
Y1 - 2025/6/5
N2 - Purpose The pathogenesis of the long-lasting symptoms which can follow an infection with the SARS-CoV-2 virus ( € long covid') is not fully understood. The € COroNaVirus post-Acute Long-term EffectS: Constructing an evidENCE base' (CONVALESCENCE) study was established as part of the Longitudinal Health and Wellbeing COVID-19 UK National Core Study. We performed a deep phenotyping case-control study nested within two cohorts (the Avon Longitudinal Study of Parents and Children and TwinsUK) as part of CONVALESCENCE. Participants From September 2021 to May 2023, 349 participants attended the CONVALESCENCE deep phenotyping clinic at University College London. Four categories of participants were recruited: cases of long covid (long covid(+)/SARS-CoV-2(+)), alongside three control groups: those with neither long covid symptoms nor evidence of prior COVID-19 (long covid(-)/SARS-CoV-2(-); control group 1), those who self-reported COVID-19 and had evidence of SARS-CoV-2 infection, but did not report long covid (long covid(-)/SARS-CoV-2(+); control group 2) and those who self-reported persistent symptoms attributable to COVID-19 but no evidence of SARS-CoV-2 infection (long covid(+)/SARS-CoV-2(-); control group 3). Remote wearable measurements were performed up until February 2024. Findings to date This cohort profile describes the baseline characteristics of the CONVALESCENCE cohort. Of the 349 participants, 141 (53±15 years old; 21 (15%) men) were cases, 89 (55±16 years old; 11 (12%) men) were in control group 1, 75 (49±15 years old; 25 (33%) men) were in control group 2 and 44 (55±16 years old; 9 (21%) men) were in control group 3. Future plans The study aims to use a multiorgan score calculated as the cumulative total for each of nine domains (ie, lung, vascular, heart, kidney, brain, autonomic function, muscle strength, exercise capacity and physical performance). The availability of data preceding acute COVID-19 infection in cohorts may help identify the consequences of infection independent of pre-existing subclinical disease and also provide evidence of determinants that influence the development of long covid.
AB - Purpose The pathogenesis of the long-lasting symptoms which can follow an infection with the SARS-CoV-2 virus ( € long covid') is not fully understood. The € COroNaVirus post-Acute Long-term EffectS: Constructing an evidENCE base' (CONVALESCENCE) study was established as part of the Longitudinal Health and Wellbeing COVID-19 UK National Core Study. We performed a deep phenotyping case-control study nested within two cohorts (the Avon Longitudinal Study of Parents and Children and TwinsUK) as part of CONVALESCENCE. Participants From September 2021 to May 2023, 349 participants attended the CONVALESCENCE deep phenotyping clinic at University College London. Four categories of participants were recruited: cases of long covid (long covid(+)/SARS-CoV-2(+)), alongside three control groups: those with neither long covid symptoms nor evidence of prior COVID-19 (long covid(-)/SARS-CoV-2(-); control group 1), those who self-reported COVID-19 and had evidence of SARS-CoV-2 infection, but did not report long covid (long covid(-)/SARS-CoV-2(+); control group 2) and those who self-reported persistent symptoms attributable to COVID-19 but no evidence of SARS-CoV-2 infection (long covid(+)/SARS-CoV-2(-); control group 3). Remote wearable measurements were performed up until February 2024. Findings to date This cohort profile describes the baseline characteristics of the CONVALESCENCE cohort. Of the 349 participants, 141 (53±15 years old; 21 (15%) men) were cases, 89 (55±16 years old; 11 (12%) men) were in control group 1, 75 (49±15 years old; 25 (33%) men) were in control group 2 and 44 (55±16 years old; 9 (21%) men) were in control group 3. Future plans The study aims to use a multiorgan score calculated as the cumulative total for each of nine domains (ie, lung, vascular, heart, kidney, brain, autonomic function, muscle strength, exercise capacity and physical performance). The availability of data preceding acute COVID-19 infection in cohorts may help identify the consequences of infection independent of pre-existing subclinical disease and also provide evidence of determinants that influence the development of long covid.
KW - COVID-19
KW - EPIDEMIOLOGY
KW - Post-Acute COVID-19 Syndrome
UR - https://www.scopus.com/pages/publications/105008095415
U2 - 10.1136/bmjopen-2024-094760
DO - 10.1136/bmjopen-2024-094760
M3 - Article
C2 - 40473290
AN - SCOPUS:105008095415
SN - 2044-6055
VL - 15
JO - BMJ Open
JF - BMJ Open
IS - 6
M1 - e094760
ER -
